OrphAI Therapeutics
Orph AI Therapeutics is focused on advancing the clinical development of therapies for rare diseases, particularly Lymphangioleiomyomatosis (LAM) and cancer. The company utilizes a technological approach that leverages big data from NextGen sequencing and chemical genomics to develop precision therapeutics. Their key products include LAM-001 and LAM-002, which are in clinical trials. Orph AI differentiates itself through its disease-specific focus and expertise in drug development, aiming to provide significant therapeutic benefits for patients. The company has received orphan drug designation for AIT-101 for ALS, indicating its strong market position and traction in the rare disease sector.
OrphAI Therapeutics
Orph AI Therapeutics is focused on advancing the clinical development of therapies for rare diseases, particularly Lymphangioleiomyomatosis (LAM) and cancer. The company utilizes a technological approach that leverages big data from NextGen sequencing and chemical genomics to develop precision therapeutics. Their key products include LAM-001 and LAM-002, which are in clinical trials. Orph AI differentiates itself through its disease-specific focus and expertise in drug development, aiming to provide significant therapeutic benefits for patients. The company has received orphan drug designation for AIT-101 for ALS, indicating its strong market position and traction in the rare disease sector.